相关实验视频

Updated: Jan 14, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

对于CHK1抑制剂发现的综合计算-实验管道:基于结构的新型化学型的鉴定具有抗癌活性

Dhanushya Gopal¹, Manasa Pacharla¹, Nehal Arvind Kumar¹

¹Department of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Chennai, India.

Naunyn-Schmiedeberg's archives of pharmacology

|October 19, 2025

概括

研究人员开发了一个计算管道,以发现用于癌症治疗的新检查点激酶1 (CHK1) 抑制剂. 该方法确定了一种有前途的化合物,AO-022/43514723,具有有利的结合和初步活性,为药物发现提供了新的框架.

科学领域:

在瘤学瘤学.
药用化学医学化学
计算生物学计算生物学

背景情况:

检查点酶1 (CHK1) 对于DNA损伤反应和细胞周期调节至关重要,使其成为癌症治疗的关键标.
现有的CHK1抑制剂面临的挑战包括选择性,毒性和耐药性,需要新的治疗策略.

研究的目的:

开发和应用一个集成的计算实验管道,用于发现新型CHK1抑制剂.
确定和验证具有改善治疗潜力的结构新CHK1抑制剂.

主要方法:

利用一个大型的化合物数据库 (规格,492,534个化合物),使用PAINS过,ECFP4指纹和UMAP/K-means集群.
采用基于结构的虚拟选,包括e-pharmacophore建模,分子对接 (Glide) 和分子动态模拟 (MM-GBSA).
在三阴性乳腺癌细胞系中通过ADME分析,合成可访问性评估和体外细胞毒性测定验证的候选者.

主要成果:

管道确定了544种不同的化合物,其中5种显示出有利的CHK1结合.
AO-022/43514723成为化合物,其对接分数为-9.205 kcal/mol,与CHK1链残留物具有稳定的相互作用.
试验室试验显示了剂量依赖的细胞毒性,IC50值为51.53μM (MDA-MB-231) 和64.02μM (MDA-MB-468),表明微分子功效.

结论:

综合管道成功识别了AO-022/43514723,一种新的初步CHK1抑制剂,具有有前途的计算和细胞活动.
这种化合物代表了进一步优化在瘤学药物发现的潜在起点.
开发的工作流提供了一个可通用的框架,用于在传统方法遇到临床障碍时发现瘤药物.

关键词:

这是一种CHK1抑制剂.分子动力学模拟模型新的化学型号新的化学型号基于结构的药物设计.三阴性乳腺癌是三阴性乳腺癌.虚拟选是一个虚拟的选.

更多相关视频

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...